Literature DB >> 3120518

Altered susceptibility of arthritic rats to the gastric lesion-inducing effects of aspirin or ethanol and the antilesion effect of rioprostil.

L B Katz1, T Genna, B L Fuller, E L Tolman, D A Shriver.   

Abstract

It is well known that nonsteroidal antiinflammatory agents produce gastric mucosal lesions in both laboratory animals and man. However, the effect of an arthritic condition on their susceptibility to ulcerogenic agents and on the efficacy of antiulcer agents is less definitive. As a model to explore these questions, the effect of oral administration of aspirin or ethanol on gastric lesion formation was examined in rats with or without established adjuvant-induced polyarthritis. In addition, the antilesion efficacy of rioprostil, a primary alcohol prostaglandin E1 analog, was evaluated in both groups of rats. The results demonstrated that arthritic rats were more sensitive to the lesion-inducing effect of aspirin, but were more resistant to the lesion-inducing effect of ethanol when compared to normal rats. An increase in endogenous gastric prostaglandin production in arthritic rats may account for their relative resistance to ethanol. Aspirin inhibited the prostaglandin synthetic capacity of the stomach in both normal and arthritic rats, which may be responsible for eliminating the relative resistance of arthritic rats to gastric irritation. Rioprostil effectively prevented aspirin or ethanol-induced lesion formation in both arthritic and nonarthritic rats, but its potency against either irritant was decreased in arthritic rats.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3120518     DOI: 10.1007/bf01968829

Source DB:  PubMed          Journal:  Agents Actions        ISSN: 0065-4299


  23 in total

1.  Development of arthritis, periarthritis and periostitis in rats given adjuvants.

Authors:  C M PEARSON
Journal:  Proc Soc Exp Biol Med       Date:  1956-01

2.  Adjuvant-induced arthritis and drug-metabolizing enzymes.

Authors:  M A Cawthorne; E D Palmer; J Green
Journal:  Biochem Pharmacol       Date:  1976-12-15       Impact factor: 5.858

3.  Role of gastric acid in aspirin-induced gastric irritation in the rat.

Authors:  D A Brodie; B J Chase
Journal:  Gastroenterology       Date:  1967-10       Impact factor: 22.682

4.  Cytoprotection by prostaglandins.

Authors:  A Robert
Journal:  Gastroenterology       Date:  1979-10       Impact factor: 22.682

5.  Formation of prostacyclin and its product 6-oxo-PGF1alpha by the gastric mucosa of several species [proceedings].

Authors:  S Moncada; J A Salmon; J R Vane; B J Whittle
Journal:  J Physiol       Date:  1978-02       Impact factor: 5.182

6.  Adjuvant polyarthritis I: incorporation of quantitative measurements of humoral and cellular immune response.

Authors:  Y H Chang
Journal:  J Pharmacol Exp Ther       Date:  1977-04       Impact factor: 4.030

7.  Chronic mild restraint protects the rat gastric mucosa from injury by ethanol or cold restraint.

Authors:  J L Wallace; N S Track; M M Cohen
Journal:  Gastroenterology       Date:  1983-08       Impact factor: 22.682

8.  The relationship between serum gastrin, gastric ulceration and basal acid output in the polyarthritic rat.

Authors:  P P Mathur; R D Smyth
Journal:  J Pharmacol Exp Ther       Date:  1980-02       Impact factor: 4.030

9.  Pharmacology of rioprostil, a new gastric cytoprotective/antisecretory agent.

Authors:  D A Shriver; M E Rosenthale; H C Kluender; R N Schut; J L McGuire; E Hong
Journal:  Arzneimittelforschung       Date:  1985

Review 10.  Prostaglandins and the gastrointestinal mucosa: are they important in its function, disease, or treatment?

Authors:  C J Hawkey; D S Rampton
Journal:  Gastroenterology       Date:  1985-11       Impact factor: 22.682

View more
  1 in total

1.  Role of mucus reduction and luminal acid elevation in increased susceptibility of stomach to nonsteroidal antiinflammatory drug-induced injury in arthritic rats.

Authors:  K Okuyama; M Jinbo; N Saito; S Igarashi; H Narita; M Kinoshita
Journal:  Dig Dis Sci       Date:  2000-11       Impact factor: 3.199

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.